Molecular & Genetic Testing Billing: CPT Codes and Reimbursement Challenges

Molecular and genetic testing is the fastest-growing category in laboratory medicine, and also the one most likely to deny. That’s not a coincidence. The coding structure behind these tests is genuinely more complex than anything in routine chemistry or hematology, the code set changes quarterly rather than annually, and payers apply an additional layer of scrutiny — a specific identifier requirement — that most labs don’t encounter anywhere else in their billing.

If your lab has expanded into next-generation sequencing, tumor profiling, or genetic panels faster than your billing team’s familiarity with molecular coding has kept pace, this is usually where the gap shows up first.

The Coding Hierarchy: PLA, Tier 1, Tier 2, and Unlisted

Molecular pathology coding follows a strict order of specificity, and using the wrong level of that hierarchy is one of the most common reasons these claims underpay or deny outright:

  1. PLA codes (Proprietary Laboratory Analyses) — sole-source or multi-provider proprietary tests, numbered in the 0001U range and up. If a PLA code exists for the specific proprietary test performed, it takes precedence over everything below it.
  2. Tier 1 codes — single-analyte molecular procedures with their own assigned CPT codes.
  3. Tier 2 codes — grouped by technical complexity, used for less common or rare-disease testing that doesn’t have its own Tier 1 code.
  4. Genomic Sequencing Procedure (GSP) codes — used for next-generation sequencing panels, but only when the entire code descriptor is fulfilled. Partial fulfillment means falling back to Tier 1 or Tier 2 instead.
  5. CPT 81479 — the unlisted molecular pathology code, used only when nothing above it applies.

The rule that trips labs up most often: 81479 isn’t a convenient fallback. If you’re using it, documentation has to name the specific gene tested, and payers scrutinize 81479 claims heavily precisely because it’s so frequently used incorrectly in place of a code that actually exists.

Why PLA Codes Are a Moving Target

Unlike most of the CPT code set, which updates once a year, the AMA releases new PLA codes on a quarterly basis. 2026 saw a substantial amount of churn in this category specifically — laboratory testing and molecular diagnostics accounted for a disproportionate share of new codes introduced this year, and PLA codes alone made up a large portion of that growth, with a number of older codes deleted and replaced by new, more specific entries.

Practically, this means a molecular test billed correctly in January can be billed incorrectly by mid-year if your coding team isn’t tracking quarterly releases — not just the annual CPT update most labs are used to watching for.

The Z-Code Requirement: The Part Most Labs Miss

This is the single most consequential detail in molecular billing, and it’s worth stating plainly: for molecular tests billed in Palmetto, Noridian, CGS, or WPS Medicare Administrative Contractor jurisdictions, the MolDX program requires a DEX Z-Code — a test-specific identifier obtained through Palmetto’s MolDX program — submitted alongside the CPT or HCPCS code on the claim.

Without an active Z-code, the test is treated as not medically necessary regardless of its actual clinical utility. That’s not a minor technicality. A clinically appropriate, correctly coded test can still deny outright if the Z-code isn’t registered and active at the time of billing. If your lab performs any molecular testing in a MolDX-participating jurisdiction, confirming Z-code status is not optional — it’s a prerequisite to getting paid at all.

Panel Billing vs. Individual Gene Codes

When an order includes a panel of 5 to 50 genes, the correct approach is billing the applicable panel code (typically in the 81445–81451 range), not the individual gene-specific codes. For panels of 51 or more genes, a separate, higher panel code applies. Billing individual gene codes when a panel code applies is treated as incorrect coding — even if every individual code is technically accurate for the gene tested, billing them separately when a panel code exists misrepresents how the test was actually performed.

This is a frequent, avoidable denial source, especially when a lab’s coding logic hasn’t been updated since a panel expanded in scope.

Why These Claims Deny More Than Routine Testing

A few factors compound to make molecular and genetic billing riskier than routine lab work:

  • Prior authorization is expanding into higher-cost molecular and genomic panels, a category that historically saw less of it than imaging or procedures.
  • Informed consent documentation is often required for genetic testing specifically, and its absence is a distinct denial trigger separate from coding accuracy.
  • Advance Beneficiary Notices (ABNs) are required when a lab has reason to believe Medicare may not consider a test reasonable or necessary — skipping this shifts financial risk back onto the lab if the claim denies.
  • Payer-to-payer inconsistency is more pronounced here than almost anywhere else in lab billing; how one commercial payer interprets a molecular coding guideline can differ meaningfully from how a MAC interprets the same scenario.

What This Means Practically

Before billing any molecular or genetic test, three checks matter more than anything else: confirm an active Z-code exists if the claim is headed to a MolDX-participating MAC, confirm the correct tier or panel code based on how many genes were actually tested, and don’t default to 81479 without documentation that names the specific gene or genes involved.

How We Handle Molecular and Genetic Billing

Molecular testing is exactly the kind of workload that benefits most from dedicated lab coding services — the code set moves quarterly, the Z-code requirement adds a compliance layer routine testing doesn’t have, and the margin for error is higher than almost anywhere else in laboratory billing. Our coders track PLA releases and MolDX Z-code requirements as part of standard workflow, not as a periodic catch-up project.

If your lab has expanded into molecular or genomic testing and your denial rate has climbed along with it, request a free billing audit through our outsourced lab billing services and we’ll show you specifically where the gaps are.

Molecular pathology and PLA codes update on a quarterly basis. Always verify current codes and MolDX Z-code status against the AMA and the relevant Medicare Administrative Contractor before billing.